CD5 positive
|
Marginal Zone Lymphoma
|
CD5 positive
|
Marginal Zone Lymphoma
|
rituximab Resistant: C3 – Early Trials
|
rituximab Resistant: C3 – Early Trials
|
CD5 positive
|
Diffuse Large B Cell Lymphoma
|
CD5 positive
|
Diffuse Large B Cell Lymphoma
|
methotrexate IV Sensitive: C3 – Early Trials
|
methotrexate IV Sensitive: C3 – Early Trials
|